CA2413328A1 - Produits pharmaceutiques pour l'imagerie de troubles angiogeniques - Google Patents
Produits pharmaceutiques pour l'imagerie de troubles angiogeniques Download PDFInfo
- Publication number
- CA2413328A1 CA2413328A1 CA002413328A CA2413328A CA2413328A1 CA 2413328 A1 CA2413328 A1 CA 2413328A1 CA 002413328 A CA002413328 A CA 002413328A CA 2413328 A CA2413328 A CA 2413328A CA 2413328 A1 CA2413328 A1 CA 2413328A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- group
- independently selected
- acid
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
- A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
L'invention concerne des composés de formule (I):(Q)¿d?-L¿n?-C¿h?, (I):utiles pour le diagnostic et le traitement de cancer en thérapie de combinaison chez un patient. Elle concerne des composés utiles dans le traitement de l'arthrite rhumatoïde. Les produits pharmaceutiques sont constitués d'une entité de ciblage qui se lie à un récepteur qui est régulé positivement durant l'angiogénèse, éventuellement d'un groupe de liaison, et d'un radio-isotope efficace sur le plan thérapeutique ou d'une entité à imagerie efficace sur le plan du diagnostic.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21320600P | 2000-06-21 | 2000-06-21 | |
US60/213,206 | 2000-06-21 | ||
PCT/US2001/020108 WO2001097860A2 (fr) | 2000-06-21 | 2001-06-21 | Produits pharmaceutiques pour l'imagerie de troubles angiogeniques |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2413328A1 true CA2413328A1 (fr) | 2001-12-27 |
Family
ID=22794144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002413328A Abandoned CA2413328A1 (fr) | 2000-06-21 | 2001-06-21 | Produits pharmaceutiques pour l'imagerie de troubles angiogeniques |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1311302A2 (fr) |
JP (1) | JP2005538030A (fr) |
AU (1) | AU2001268710A1 (fr) |
CA (1) | CA2413328A1 (fr) |
WO (1) | WO2001097860A2 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
CA2727746A1 (fr) | 1998-12-18 | 2000-06-22 | Bristol-Myers Squibb Pharma Company | Medicaments antagonistes du recepteur de la vitronectine de quinolone |
US6511649B1 (en) | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
WO2001097848A2 (fr) * | 2000-06-21 | 2001-12-27 | Bristol-Myers Squibb Pharma Company | Agents pharmaceutiques antagonistes du recepteur de vitronectine, a utiliser en polytherapie |
CA2412849A1 (fr) * | 2000-06-21 | 2001-12-27 | Bristol-Myers Squibb Pharma Company | Agents pharmaceutiques antagonistes du recepteur de la vitronectine destines a etre utilises dans une therapie combinee |
US6827926B2 (en) * | 2001-05-31 | 2004-12-07 | Miravant Pharmaceuticals, Inc. | Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
EP1587944A4 (fr) | 2002-03-01 | 2007-03-21 | Dyax Corp | Peptides de liaison kdr et vegf/kdr et leur utilisation a des fins diagnostiques et therapeutiques |
US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
WO2003074005A2 (fr) * | 2002-03-01 | 2003-09-12 | Dyax Corp. | Peptides liant des recepteurs kdr et vegf/kdr et leurs utilisations en diagnostic et therapie |
US9957293B2 (en) | 2006-08-23 | 2018-05-01 | Yeda Research And Development Company Ltd. | Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses |
WO2008090731A1 (fr) | 2007-01-23 | 2008-07-31 | Pola Pharma Inc. | Procédé de production de dérivé de 2-nitro-imidazole |
PT3158991T (pt) | 2010-01-28 | 2021-06-23 | Eagle Pharmaceuticals Inc | Formulações de bendamustina |
EP3101012A1 (fr) | 2015-06-04 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | Nouveaux composés de chélate de gadolinium pour une utilisation dans l'imagerie par résonance magnétique |
KR101769911B1 (ko) | 2015-11-09 | 2017-08-21 | 포항공과대학교 산학협력단 | 신규한 항암제로서 Skp2 저해제 |
RU2755181C2 (ru) | 2016-11-28 | 2021-09-14 | Байер Фарма Акциенгезельшафт | Новые хелатные соединения гадолиния с высокой релаксивностью для применения в магнитно-резонансной визуализации |
MX2021006024A (es) | 2018-11-23 | 2021-07-06 | Bayer Ag | Formulacion de medios de contraste y proceso para prepararlos. |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU9477398A (en) * | 1997-09-10 | 1999-03-29 | Burnham Institute, The | Methods of identifying molecules that home to angiogenic vasculature in tumors |
IL138093A0 (en) * | 1998-03-31 | 2001-10-31 | Du Pont Pharm Co | Pharmaceuticals for the imaging of angiogenic disorders |
AU2002218751A1 (en) * | 2000-07-06 | 2002-01-21 | Bristol-Myers Squibb Pharma Company | Stable radiopharmaceutical compositions |
-
2001
- 2001-06-21 CA CA002413328A patent/CA2413328A1/fr not_active Abandoned
- 2001-06-21 JP JP2002503343A patent/JP2005538030A/ja active Pending
- 2001-06-21 EP EP01946697A patent/EP1311302A2/fr not_active Withdrawn
- 2001-06-21 AU AU2001268710A patent/AU2001268710A1/en not_active Abandoned
- 2001-06-21 WO PCT/US2001/020108 patent/WO2001097860A2/fr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2001097860A3 (fr) | 2003-02-27 |
AU2001268710A1 (en) | 2002-01-02 |
WO2001097860A2 (fr) | 2001-12-27 |
JP2005538030A (ja) | 2005-12-15 |
EP1311302A2 (fr) | 2003-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6537520B1 (en) | Pharmaceuticals for the imaging of angiogenic disorders | |
EP1068224B1 (fr) | Produits pharmaceutiques pour l'imagerie de troubles angiogenes | |
AU2007201609A1 (en) | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | |
US20020122768A1 (en) | Stable radiopharmaceutical compositions and methods for preparation thereof | |
CA2413328A1 (fr) | Produits pharmaceutiques pour l'imagerie de troubles angiogeniques | |
CA2412849A1 (fr) | Agents pharmaceutiques antagonistes du recepteur de la vitronectine destines a etre utilises dans une therapie combinee | |
CA2349333A1 (fr) | Medicaments antagonistes du recepteur de la vitronectine | |
US6548663B1 (en) | Benzodiazepine vitronectin receptor antagonist pharmaceuticals | |
US7090828B2 (en) | Vitronectin receptor antagonist pharmaceuticals | |
CA2412854C (fr) | Agents pharmaceutiques antagonistes du recepteur de vitronectine, a utiliser en polytherapie | |
US6818659B2 (en) | (2S)-2-amino-4-(2-amino-(3,4,5,6-tetrahydropyrimidin-4-yl) butanoyl and its use in cyclic and acyclic peptides | |
AU2002243238A1 (en) | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | |
MXPA00009574A (en) | Pharmaceuticals for the imaging of angiogenic disorders | |
CZ20003353A3 (cs) | Farmaceutické sloučeniny pro zobrazování poruch angiogeneze |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |